The case for
Metabolic drugs turned out to affect far more than weight. Sequencing costs fell far enough to make genetic medicine economic, and the payer is a demographic wave already here.
Medicine shifts from treating disease late to extending the years a person stays healthy.
Universe v1 (assumed — this link predates the field)· No stated date on this link
Every holding, and why it is that size
Restore the book27.2%Eli Lilly
The broadest metabolic franchise and deepest follow-on pipeline.
LLY · Equity · $370.14 · $2.38T · Healthspan
−+×21.7%Novo Nordisk
The other half of the metabolic duopoly, with more pricing exposure.
NVO · Equity · $32.58 · $10B · Healthspan
−+×13.6%Regeneron
An antibody platform that has produced beyond one franchise.
REGN · Equity · $185.13 · $5B · Healthspan
−+×13.2%Thermo Fisher Scientific
Tools and reagents; paid whether or not a trial reads out.
TMO · Equity · $166.52 · $16B · Healthspan
−+×8.3%Biotech ETF
Spread across small-cap biotech, where single-name risk is brutal.
XBI · ETF · $8.62 · $69B · Healthspan
−+×16%0–3 Month Treasury Bill ETF
Cash that still earns while the thesis is early.
SGOV · Treasury · $161.00 · $106B · Ballast
The case against
Drug pricing is a political target in every developed market. Patents expire on schedule, trials fail late and expensively, and the largest products already carry near-perfect expectations.
What the weights are worth
Percentages, converted. Nothing is sent anywhere.
Enter an amount to see what each weight is worth. It stays in this browser.
This book has an address
Anyone who opens it rebuilds the same book, weight for weight.
igitur.xyz/b/medicine-shifts-from-treating-disease-late-moqte7